{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:27:09Z","timestamp":1790900829178,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.jaad.2009.12.013","type":"journal-article","created":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T02:19:44Z","timestamp":1269483584000},"page":"413-422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Intralesional agents in the management of cutaneous malignancy: A review"],"prefix":"10.1016","volume":"64","author":[{"given":"Laurie M.","family":"Good","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney A.","family":"High","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2009.12.013_bib1","unstructured":"American Cancer Society. Cancer facts and figures. Available from: URL:http:\/\/www.cancer.org\/downloads\/STT\/500809web.pdf. Accessed July 26, 2009."},{"key":"10.1016\/j.jaad.2009.12.013_bib2","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1056\/NEJMra044151","article-title":"Basal-cell carcinoma","volume":"353","author":"Rubin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2009.12.013_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1524-4725.1989.tb03166.x","article-title":"Long-term recurrence rates in previously untreated (primary) cell carcinoma: implications for patient follow-up","volume":"15","author":"Rowe","year":"1989","journal-title":"J Dermatol Surg Oncol"},{"key":"10.1016\/j.jaad.2009.12.013_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2009.12.013_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/120347540300700201","article-title":"Topical treatment of Bowen's disease with 5-florouracil","volume":"7","author":"Bargman","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaad.2009.12.013_bib6","first-page":"433","article-title":"5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction","volume":"33","author":"Gross","year":"2007","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2009.12.013_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0190-9622(97)70328-1","article-title":"Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil\/epinephrine injectable gel","volume":"36","author":"Miller","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jaad.2009.12.013_bib9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/978-3-642-59410-6_29","article-title":"Intralesional interferon in basal cell carcinoma: how does it work?","volume":"160","author":"Buechner","year":"2002","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.jaad.2009.12.013_bib10","article-title":"Interventions for basal cell carcinoma of the skin [review]","volume":"Jan24","author":"Bath-Hextall","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2009.12.013_bib11","first-page":"558","article-title":"Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicenter study","volume":"12","author":"Kowalzick","year":"2002","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib12","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/0190-9622(90)70276-N","article-title":"Intralesional interferon therapy for basal cell carcinoma","volume":"23","author":"Cornell","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/archderm.1990.01670320053006","article-title":"The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas","volume":"126","author":"Edwards","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1346-8138.1996.tb04040.x","article-title":"Comparison of the effects of intralesional interferon alfa-2a, 2b, and the combination of 2a and 2b in the treatment of basal cell carcinoma","volume":"23","author":"Alpsoy","year":"1996","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000246688","article-title":"Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma","volume":"190","author":"Chimenti","year":"1995","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2009.12.013_bib16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jaad.2006.02.035","article-title":"Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa-2b as monotherapy","volume":"54","author":"Tucker","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0190-9622(92)70158-C","article-title":"Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery","volume":"27","author":"Stenquist","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-4632.2009.03576.x","article-title":"Treatment of infiltrating basal cell carcinoma with the combination of intralesional IFN\u03b1-2b and topical imiquimod 5% cream","volume":"48","author":"Turan","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0190-9622(08)80545-2","article-title":"Intralesional interferon therapy for basal cell carcinoma [letter]","volume":"26","author":"Epstein","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1524-4725.2000.0260111037.x","article-title":"Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma","volume":"26","author":"Kaplan","year":"2001","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2009.12.013_bib21","series-title":"Cancer chemotherapy handbook","first-page":"274","year":"1980"},{"key":"10.1016\/j.jaad.2009.12.013_bib22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archderm.1994.01690050045006","article-title":"Intradermal bleomycin injections into normal human skin","volume":"130","author":"Templeton","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0190-9622(96)90838-5","article-title":"Bleomycin-mediated electrochemotherapy of basal cell carcinoma","volume":"34","author":"Glass","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib24","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0190-9622(97)70178-6","article-title":"Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma","volume":"37","author":"Glass","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0188-4409(01)00278-8","article-title":"Electrochemotherapy in primary and metastatic skin tumors: phase II trials using bleomycin","volume":"32","author":"Rodriguez-Cuevas","year":"2001","journal-title":"Arch Med Res"},{"key":"10.1016\/j.jaad.2009.12.013_bib26","first-page":"25","article-title":"Intralesional bleomycin as alternative therapy in the treatment of multiple basal cell carcinomas","volume":"12","author":"Gyurova","year":"2006","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2009.12.013_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1179\/joc.2004.16.5.491","article-title":"New proposal for the treatment of nodular basal cell carcinoma with intralesional 5-sminolevulinic acid","volume":"16","author":"Cappugi","year":"2004","journal-title":"J Chemother"},{"key":"10.1016\/j.jaad.2009.12.013_bib28","unstructured":"Skin Cancer Foundation. Skin cancer facts. Available from: URL:http:\/\/skincancer.org\/Skin-Cancer-Facts\/. Accessed July 28, 2009."},{"key":"10.1016\/j.jaad.2009.12.013_bib29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1524-4725.1990.tb00080.x","article-title":"Aggressive keratoacanthoma of the eyelid: \u201cmalignant\u201d keratoacanthoma or squamous cell carcinoma?","volume":"16","author":"Requena","year":"1990","journal-title":"J Dermatol Surg Oncol"},{"key":"10.1016\/j.jaad.2009.12.013_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00000372-199308000-00007","article-title":"Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases","volume":"15","author":"Hodak","year":"1993","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2009.12.013_bib31","first-page":"153","article-title":"Keratoacanthoma: local effect of 5-fluorouracil","volume":"1","author":"Klein","year":"1962","journal-title":"Skin"},{"key":"10.1016\/j.jaad.2009.12.013_bib32","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1001\/archderm.1978.01640240021006","article-title":"Treatment of keratoacanthomas with intralesional fluorouracil","volume":"114","author":"Odom","year":"1978","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0190-9622(80)80007-7","article-title":"Successful treatment of keratoacanthoma with intralesional fluorouracil","volume":"2","author":"Goette","year":"1980","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0190-9622(82)80019-4","article-title":"Treatment of multiple keratoacanthomas with intralesional fluorouracil","volume":"7","author":"Eubanks","year":"1982","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib35","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0190-9622(86)70092-3","article-title":"Large keratoacanthomas in difficult locations treated with intralesional 5-fluoruracil","volume":"14","author":"Parker","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0190-9622(98)70502-X","article-title":"Intratumoral chemotherapy with fluorouracil\/epinephrine injectable gel: a nonsurgical treatment of cutaneous squamous cell carcinoma","volume":"38","author":"Kraus","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib37","first-page":"1150","article-title":"Treatment of squamous cell carcinoma with intralesional 5-fluorouracil","volume":"29","author":"Morse","year":"2003","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2009.12.013_bib38","first-page":"454","article-title":"Treatment of giant keratoacanthoma with intralesional 5-fluorouracil","volume":"5","author":"Leonard","year":"2006","journal-title":"Drugs Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0190-9622(91)70199-C","article-title":"The pharmacology of methotrexate","volume":"25","author":"Olsen","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib40","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaad.2006.12.017","article-title":"Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature","volume":"56","author":"Annest","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib41","first-page":"1104","article-title":"Pancytopenia after treatment of keratoacanthoma by single lesional methotrexate infiltration","volume":"137","author":"Goebeler","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib42","first-page":"648","article-title":"Pancytopenia after a single intradermal infiltration of methotrexate","volume":"4","author":"Cohen","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0190-9622(89)70009-8","article-title":"Treatment of neoplastic skin lesions with intralesional interferon","volume":"20","author":"Wickramasinghe","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0190-9622(93)70174-R","article-title":"Large keratoacanthomas treated with intralesional interferon alfa-2a","volume":"29","author":"Grob","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2009.12.013_bib45","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/j.jaad.2004.05.009","article-title":"Intralesional interferon alfa-2b treatment of keratoacanthomas","volume":"51","author":"Oh","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2133.1983.tb04619.x","article-title":"Treatment of keratoacanthoma with intralesional bleomycin","volume":"109","author":"Sayama","year":"1983","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib47","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0190-9622(97)70089-6","article-title":"Keratoacanthoma centrifugum marginatum: treatment with intralesional bleomycin","volume":"37","author":"De la Torre","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib48","first-page":"403","article-title":"Guess what! Keratoacanthoma treated with intralesional bleomycin","volume":"9","author":"Andreassi","year":"1999","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib49","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/10428190500399698","article-title":"Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma","volume":"47","author":"Cozzio","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"Suppl","key":"10.1016\/j.jaad.2009.12.013_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.0303-6987.2006.00544.x","article-title":"Standard and new treatments in cutaneous B-cell lymphomas","volume":"33","author":"Dreno","year":"2006","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2009.12.013_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000051734","article-title":"Large B-cell lymphoma of the leg\u2013complete remission with perilesional interferon alpha","volume":"203","author":"Wollina","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2009.12.013_bib52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s004320050144","article-title":"Complete response of a primary cutaneous T-cell-rich B cell lymphoma treated with interferon alpha2a","volume":"124","author":"Wollina","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jaad.2009.12.013_bib53","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","article-title":"Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases","volume":"155","author":"Kerl","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib54","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2005.01.093","article-title":"Treatment of primary cutaneous B-cell lymphoma with rituximab","volume":"52","author":"Fink-Puches","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00000421-200106000-00005","article-title":"Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab)","volume":"24","author":"Aboulafia","year":"2001","journal-title":"Am J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2009.12.013_bib56","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/j.jaad.2005.11.1037","article-title":"Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate","volume":"54","author":"Blume","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2009.12.013_bib57","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1468-3083.2006.01958.x","article-title":"Therapeutic use of mistletoe for CD30+ cutaneous lymphoproliferative disorder\/lymphomatoid papulosis","volume":"21","author":"Seifert","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2009.12.013_bib58","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00687330","article-title":"Local treatment of cutaneous and subcutaneous metastatic malignant melanoma with fotemustine","volume":"29","author":"Schallreuter","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaad.2009.12.013_bib59","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/1097-0142(197806)41:6<2456::AID-CNCR2820410654>3.0.CO;2-B","article-title":"Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene","volume":"4","author":"Cohen","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2009.12.013_bib60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00008390-200304000-00016","article-title":"Regression of a cutaneous melanoma metastasis after intralesional cidofovir","volume":"13","author":"Calista","year":"2003","journal-title":"Melanoma Res"},{"issue":"Suppl","key":"10.1016\/j.jaad.2009.12.013_bib61","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/00008390-200609001-00012","article-title":"Rose bengal induces dual modes of cell death in melanoma cells and has clinical\u00a0activity against melanoma","volume":"16","author":"Mousavi","year":"2006","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2009.12.013_bib62","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000117707","article-title":"Systemic phototoxicity following intralesional rose bengal for subcutaneous melanoma metastases","volume":"216","author":"Wiener","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2009.12.013_bib63","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/CMR.0b013e328331caa2","article-title":"A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series","volume":"20","author":"Foote","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2009.12.013_bib64","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<148::AID-CNCR20>3.0.CO;2-W","article-title":"Treatment of\u00a0cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin","volume":"83","author":"Heller","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2009.12.013_bib65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00008390-200502000-00008","article-title":"Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy)","volume":"15","author":"Byrne","year":"2005","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jaad.2009.12.013_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2310\/7750.2006.00037","article-title":"Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma","volume":"10","author":"Gaudy","year":"2006","journal-title":"J Cutan Med Surg"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096220902283X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096220902283X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:18:57Z","timestamp":1759270737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096220902283X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S019096220902283X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2009.12.013","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intralesional agents in the management of cutaneous malignancy: A review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2009.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}